Creative Medical Technology Holdings Reports 93% Response Rate in Six-Month Pilot Study of Investigational Ultrasome for Knee Osteoarthritis
The open-label, single-arm study followed 30 patients with bilateral knee osteoarthritis for six months; no serious adverse events were reported.

Key Points
- Creative Medical Technology Holdings reported that 28 of 30 patients (93%) met response criteria in a six-month pilot study of its investigational Ultrasome platform for knee osteoarthritis.
- The group’s average pain score declined approximately 65% from baseline, and the average WOMAC score improved by 52%.
- The open-label, single-arm study lacked a randomized or sham-controlled comparator, and no serious adverse events were reported during follow-up.
Creative Medical Technology Holdings, a clinical-stage biotechnology company advancing regenerative medicine technologies, highlighted additional clinical and laboratory findings for Ultrasome, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy held October 10, 2026, in Lima, Peru.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
The study evaluated 30 patients with bilateral knee osteoarthritis over six months and found that 28 of 30 participants (93%) met study-defined response criteria. The group’s average reported pain score declined by approximately 65% from baseline to six months. The 65% figure refers to the reduction in the group-average pain score, not the percentage of patients reporting improvement. The study was an open-label, single-arm pilot without a randomized or sham-controlled comparator.
Clinical Results
In addition to the 93% response rate and 65% reduction in average pain score, the group’s average WOMAC score, reflecting osteoarthritis-related pain, stiffness and physical limitations, improved by 52% over six months. The group’s average knee-related quality-of-life score increased by approximately 35 points. No serious adverse events were reported during six months of follow-up.
Additional Scientific Findings
Laboratory studies demonstrated significant reductions in biological markers associated with cartilage degradation and inflammatory signaling. Product characterization and functional potency testing also provided what the company described as encouraging findings supporting further evaluation of manufacturing quality controls and product consistency. Creative Medical anticipates that the full scientific findings, including detailed potency analyses, statistical evaluations, tables and figures, will be included in a manuscript planned for peer-reviewed publication.
Ultrasome builds upon Creative Medical’s regenerative medicine technology platform associated with CELZ-201 (Olastrocel), using extracellular-vesicle-rich secretome material in an investigational cell-free therapeutic approach. The company believes this strategy may offer potential future advantages in manufacturing, distribution and development across osteoarthritis and other degenerative conditions. Ultrasome is not FDA-approved for knee osteoarthritis or other indications.
“These findings represent an encouraging milestone for Ultrasome,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “With 93% of patients meeting study-defined response criteria and an approximately 65% reduction in the group’s average pain score, we believe the results strengthen the rationale for further development. The additional potency findings reinforce our focus on a scalable, biologically active regenerative medicine platform with significant long-term opportunity.”
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Shanghai Jiao Tong University School of Medicine Tests Intranasal Umbilical Cord Exosomes for Early Parkinson’s Disease
Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes
New Trial – Mesenchymal Stem Cell Exosomes for Non-Dialysis Chronic Kidney Disease
NurExone and NanoPass Developing Stem Cell Exosomes for Eye and Skin Regeneration
Celularity to Manufacture MuseCell Innovations Therapies in the US
Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy Facility
Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies
Mesenchymal Stem Cell Extracellular Vesicles Reprogram Microglia and Prevent Neurodegeneration in Alzheimer’s Models







